octreotide acetate
octreotide acetate is listed in the FDA National Drug Code directory with 26 NDC codes, marketed under brand names including Sandostatin, Octreotide Acetate, Sandostatin LAR Depot. Available dosage forms: injection, solution, powder, kit, injection.
Drug Details
- Generic Name
- octreotide acetate
- Brand Names
- Sandostatin, Octreotide Acetate, Sandostatin LAR Depot, OCTREOTIDE ACETATE, BYNFEZIA Pen
- Application Number
- NDA019667
- Sponsor
- Novartis Pharmaceuticals Corporation
- NDC Codes
- 26
- Dosage Forms
- INJECTION, SOLUTION, POWDER, KIT, INJECTION
- Routes
- INTRAVENOUS, SUBCUTANEOUS
- Active Ingredients
- OCTREOTIDE ACETATE
Indications and Usage
1 INDICATIONS AND USAGE Octreotide acetate for injectable suspension 10 mg, 20 mg, and 30 mg is indicated in patients in whom initial treatment with octreotide acetate injection has been shown to be effective and tolerated. Octreotide acetate for injectable suspension is a somatostatin analogue indicated for: Treatment in patients who have responded to and tolerated octreotide acetate injection subcutaneous injection for: Acromegaly ( 1.1 ) Severe diarrhea/flushing episodes associated with metastatic carcinoid tumors ( 1.2 ) Profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP) secreting tumors ( 1.3 ) 1.1 Acromegaly Long-term maintenance therapy in acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy, is not an option. The goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal [see Clinical Studies ( 14 ), Dosage and Administration ( 2 )] . 1.2 Carcinoid Tumors Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors. 1.3 Vasoactive Intestinal Peptide Tumors (VIPomas) Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors. 1.4 Important Limitations of Use In patients with carcinoid syndrome and VIPomas, the effect of octreotide acetate injection and octreotide acetate for injectable suspension on tumor size, rate of growth and development of metastases, has not been determined.